Peptide Comparison
MacimorelinvsCJC-1295 with DAC
FDA-approved diagnostic test for adult growth hormone deficiency
Long-acting growth hormone releaser that works around the clock to boost your body's natural GH production with just one or two injections per week.
At a Glance
Quick
comparison
Dose Range
Macimorelin
25–60 mg
CJC-1295 with DAC
1000–2000 mcg
Frequency
Macimorelin
As needed
CJC-1295 with DAC
Twice weekly
Administration
Macimorelin
Oral (reconstituted solution)
CJC-1295 with DAC
Subcutaneous injection
Cycle Length
Macimorelin
4-6 weeks
CJC-1295 with DAC
8-12 weeks
Onset Speed
Macimorelin
Rapid (hours to days)
CJC-1295 with DAC
Moderate (1-2 weeks)
Evidence Level
Macimorelin
Strong human trials (Phase 3 or FDA approved)
CJC-1295 with DAC
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Diagnostic Accuracy
Safety & Tolerability
Convenience & Patient Experience
GH Elevation
Convenience
Recovery Support
Technical Data
Compound
specifications
Macimorelin
Molecular Formula
C26H30N6O3
Molecular Weight
474.6 g/mol
Half-Life
4.1 hours
Bioavailability
Oral; food decreases Cmax and AUC by approximately 50-55% — must be administered fasting
CAS Number
381231-18-1
CJC-1295 with DAC
Molecular Formula
C165H269N47O46
Molecular Weight
3647.28 g/mol
Half-Life
6-8 days
Bioavailability
~100% (subcutaneous)
CAS Number
863288-34-0
Protocols
Dosing
tiers
Macimorelin
CJC-1295 with DAC
Applications
Best
suited for
Macimorelin
Diagnosis of Adult Growth Hormone Deficiency
Macimorelin is FDA-approved specifically for diagnosing AGHD in adults. It replaces the insulin tolerance test (ITT) as a safer, more convenient, and equally accurate diagnostic option. Phase 3 trials showed 87% sensitivity and 96% specificity.
Patients Intolerant or Contraindicated for ITT
For patients who cannot safely undergo insulin tolerance testing due to cardiac risk, seizure history, or other contraindications, macimorelin offers an evidence-based non-invasive alternative.
Clinical Confirmation Testing
With 97% reproducibility on retesting, macimorelin can reliably confirm GH deficiency diagnoses and monitor therapeutic responses over time with excellent consistency.
CJC-1295 with DAC
Growth Hormone Optimization
CJC-1295 with DAC excels at providing a sustained, steady elevation of growth hormone levels. Unlike shorter-acting peptides that create brief spikes, the DAC modification keeps GH elevated for days, mimicking a more youthful hormone profile.
Muscle Building and Recovery
By increasing both GH and IGF-1 levels, this peptide supports protein synthesis and muscle repair. Users often notice improved recovery between workouts and better ability to build and maintain lean muscle mass.
Anti-Aging and Longevity
Growth hormone naturally declines with age, contributing to many signs of aging. CJC-1295 with DAC helps restore more youthful GH levels, potentially supporting better skin quality, energy levels, and overall vitality.
Body Composition Improvement
The combination of increased GH and IGF-1 promotes fat metabolism while preserving muscle tissue. Many users experience gradual fat loss, particularly in stubborn areas, while maintaining or building lean mass.
Convenient Weekly Dosing
Unlike peptides requiring daily or twice-daily injections, the extended half-life of CJC-1295 with DAC means just one or two injections per week provide continuous benefits. Ideal for those who want results without daily protocols.
Safety Profile
Side
effects
Macimorelin
Common
- Dysgeusia (abnormal taste)
- Dizziness
- Headache
- Fatigue
- Nausea
- Increased Appetite
Serious
- Cardiovascular events
CJC-1295 with DAC
Common
- Injection site reactions
- Water retention
- Flushing
- Tingling sensation
Uncommon
- Headaches
- Fatigue or lethargy
- Joint discomfort
Serious
- Carpal tunnel symptoms
- Blood glucose elevation
Research Status
Safety
& evidence
Macimorelin
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
FDA approved for this use
Safety Overview
Macimorelin is well-tolerated with an excellent safety profile in clinical trials. No serious adverse events were reported in Phase 3 studies (n=154). Most side effects are mild and transient. QT prolongation of approximately 11 msec occurs but is generally not clinically significant. However, avoid combining with other QT-prolonging drugs.
Contraindications
- xPatients with QT prolongation or QT/RR prolongation disorder
- xConcurrent use with drugs known to prolong QT interval
- xPatients with critical illness (acute medical or surgical illness)
- xKnown hypersensitivity to macimorelin or any components
- xPatients unable to fast or follow fasting requirements
CJC-1295 with DAC
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
CJC-1295 with DAC was evaluated in Phase 1-2 human clinical trials where it demonstrated a generally favorable safety profile. The most common adverse events were mild injection site reactions including temporary pain, swelling, and redness. No serious adverse events were reported in the published clinical studies. The compound was being developed for HIV-associated lipodystrophy before the program was discontinued.
Contraindications
- xActive cancer or history of malignancy
- xPregnancy or breastfeeding
- xPituitary tumors or disorders
- xDiabetic retinopathy
- xUncontrolled diabetes
Decision Guide
Which is
right for you?
Choose Macimorelin if...
- Diagnosing adult growth hormone deficiency (AGHD)
- Patients who cannot tolerate or are contraindicated for insulin tolerance test
- Clinical settings requiring convenient, repeatable hormone testing
- Healthcare providers seeking FDA-approved diagnostic alternatives
Choose CJC-1295 with DAC if...
- Boosting natural growth hormone production
- Building lean muscle mass
- Improving body composition
- Anti-aging and longevity